NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia (Q37790694)

23 August 2017

title

NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia (English)

1 reference

23 August 2017

0 references

1 reference

2

Giuliana Alimena

1 reference

23 August 2017

1

Massimo Breccia

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

full work available at URL

23 August 2017

http://www.informapharmascience.com/doi/abs/10.1517/14728222.2010.522570

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858024

http://www.tandfonline.com/doi/pdf/10.1517/14728222.2010.522570

17 July 2024

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Expert Opinion on Therapeutic Targets

17 July 2024

published in

1 reference

23 August 2017

volume

14

1 reference

23 August 2017

issue

11

1 reference

23 August 2017

page(s)

1157-1176

1 reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

21 January 2018

Acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Myelodysplastic syndromes classification and risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

NF-kappaB and IKK as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Targeting NF-kappaB in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

NF-kappa B: ten years after

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Nuclear factor-kappaB: the enemy within

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

21 January 2018

Signaling to NF-kappaB

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

The IKK NF-kappa B system: a treasure trove for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Control of nuclear factor-kappa B DNA-binding activity by inhibitory proteins containing ankyrin repeats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

NF-kappaB as a potential molecular target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

NF-kappaB inhibition: a double-edged sword in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Nuclear transcription factor-kappaB as a target for cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Aberrant rel/nfkb genes and activity in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

B-cell lymphoma of MALT type: a review with special emphasis on diagnostic and management problems of low-grade gastric tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Expression of FLIPLong and FLIPShort in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Nuclear factor kB as a target for new drug development in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Phase I study of bortezomib in refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Thalidomide for the Treatment of Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Thalidomide for the treatment of patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Inhibitors of NF-kappaB signaling: 785 and counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Distinct combinatorial effects of the plant polyphenols curcumin, carnosic acid, and silibinin on proliferation and apoptosis in acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Proteasome inhibition drastically but reversibly impairs murine lymphocyte development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Activation of the wt1 Wilms' tumor suppressor gene by NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

MALT lymphoma: from morphology to molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Constitutive NF-κB/Rel Activation in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.522570

Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts

21 January 2018

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/SJ.LEU.2402641

Acute myeloid leukemia

1

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Novel therapies for myelodysplastic syndromes

17 July 2024

5

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Biochimica et Biophysica Acta

17 July 2024

9

1470

M55

Mayo MW

2000

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Protein-protein interactions involving IKKgamma (NEMO) that promote the activation of NF-kappaB.

17 July 2024

19

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells

17 July 2024

55

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells

17 July 2024

57

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

17 July 2024

63

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

17 July 2024

66

87

1005

Sanz C

2002

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis

17 July 2024

78

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

17 July 2024

80

94

Breccia M

2009

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia

17 July 2024

117

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS

17 July 2024

119

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines

17 July 2024

133

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.522570

17 July 2024

Identifiers

1 reference

23 August 2017

1 reference